C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/11 (2006.01) A61K 31/7088 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2686908
The invention relates to oligomeric compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3 and/or HER2 and/or EGFR. Reduction of HER3 and/or HER2 and/or EGFR expression is beneficial for a range of medical disorders, such as hyperproliferative diseases, including cancer. The invention provides therapeu tic compositions comprising oligomers and methods for modulating the expression of HER3 and/or HER2 and/or EGFR using said oligomers, including methods of treatment.
L'invention porte sur des composés oligomères ciblant le HER3 et l'ARNm d'une cellule, réduisant ainsi l'expression du HER3 et-ou du HER2 et-ou du EGFR. La réduction de l'expression du HER3 et-ou du HER2 et-ou du EGFR est bénéfique pour une série de troubles médicaux, tels que les maladies hyperproliférantes dont le cancer. L'invention porte également sur des compositions thérapeutiques comprenant lesdits oligomères, et sur des méthodes modulant l'expression de HER3 et-ou HER2 et-ou du EGFR utilisant lesdits oligomères.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Enzon Pharmaceuticals Inc.
Santaris Pharma A/s
LandOfFree
Rna antagonist compounds for the modulation of her3 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rna antagonist compounds for the modulation of her3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rna antagonist compounds for the modulation of her3 will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1496384